1 / 18

EURAMOS 1

EURAMOS 1. A randomised trial of the European and American Osteosarcoma Study Group to optimize treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy. Jeremy Whelan for the EURAMOS 1 Trial Management Group, 4 th November 2006. EURAMOS.

roz
Download Presentation

EURAMOS 1

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. EURAMOS 1 A randomised trial of the European and American Osteosarcoma Study Group to optimize treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy Jeremy Whelan for the EURAMOS 1 Trial Management Group, 4th November 2006

  2. EURAMOS • EURAMOS is the European and American Osteosarcoma Study Group. The study was founded in 2001. • Children’s Oncology Group • Cooperative Osteosarcoma Study Group • European Osteosarcoma Intergroup • Scandinavian Sarcoma Group

  3. EURAMOS • Established Oct 2001 • Aim • to improve survival from OS • Objectives • to carry out large international randomised trials • to facilitate biological research • to seek new therapeutic approaches • to develop common understanding and methodologies for staging, pathology etc.

  4. EURAMOS 1 • Co-sponsored • MRC in Europe • COG for North America • Co-ordinating Data Centre • MRC Clinical Trials Unit

  5. Trial Design

  6. Trial Design • Key registration criteria • High grade OS of extremity or axial skeleton • Resectable disease • Fit for treatment

  7. Trial Design • Key randomisation criteria • Adequate pre-operative chemotherapy • Macroscopically complete resection of primary tumour • Complete removal of all metastases or complete removal planned and feasible • Histological response assessment

  8. Trial Design • Primary Objectives • Addition of IE to post-op MAP chemotherapy improves EFS for poor responders • Addition of ifn to post-op MAP chemotherapy improves EFS for good responders

  9. Trial Design • Secondary Objectives • Additional treatment improves OS, short and long term toxicity and quality of life • Additional treatment improves EFS in localised disease • Investigate biological and clinical correlated to histological response and outcome • International cooperation in trials • Examine outcome of the entire cohort of patients

  10. Trial Design- additional studies • Quality of Life • Biology Studies

  11. EURAMOS participants

  12. Progress: open and recruiting

  13. Progress: almost ready • Austria • Finland

  14. Progress: requests to join • Czech Republic • Ireland • Poland • Israel

  15. Accrual 302 Registered

  16. Accrual • 302 Registered

  17. Accrual 123 Randomised

  18. EURAMOS 1 • Chief Investigators • Mark Bernstein (TMG Chair) • Neyssa Marina (COG) • Stephan Bielack (COSS) • Jeremy Whelan (EOI) • Sigbjorn Smeland (SSG) • Website • www.euramos.org

More Related